Trial Profile

A Phase 2 Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With Thymidine Kinase 2 Deficiency (TK2)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deoxycytidine/deoxythymidine (Primary)
Indications Mitochondrial disorders
Focus Adverse reactions
Acronyms Continuation
Sponsors Modis Therapeutics; UCB Biosciences

Most Recent Events

19 Mar 2025 According to a UCB media release, the pooled data form two retrospective ((NCT03701568, NCT05017818) trials and this prospective trials and a company-supported expanded access program (EAP) were presented at the MDA Clinical and Scientific Conference, Dallas, Texas, March 16-19, 2025.
19 Mar 2025 Results presented in the UCB Media Release.
17 Nov 2023 Planned End Date changed from 24 Jun 2026 to 18 Jun 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com